FGF23 and hyperphosphatemia: While highly elevated FGF23 levels in patients with CKD are associated with faster progression to the requirement for kidney replacement therapy, cardiovascular morbidity and mortality (see below), neutralization of FGF23 in rodent models of CKD has shown detrimental effects causing hyperphosphatemia with excessive vascular calcification and early mortality [14].